文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

HLA免疫肽组差异对非亲缘供者移植后白血病患者生存的影响

Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation.
PubMed 文献 · J Clin Oncol · 2023-01-20

研究纳入2008至2018年间2391例单类I HLA错配和14426例全相合非亲缘供者造血细胞移植,以实验确定的肽结合基序层次聚类评估免疫肽组差异。结果显示移植物抗宿主方向PBM错配者总生存显著低于全相合(HR 1.48,P<.0001),且移植相关死亡和急慢性GVHD风险逐步升高,而复发未增加。

要点

  • 单类I HLA错配移植中,移植物抗宿主方向PBM错配与总生存降低相关(HR 1.48,P<.0001)。
  • PBM-GVH错配者移植相关死亡及急慢性GVHD风险从全相合到单PBM-GVH匹配再到单PBM-GVH错配逐步升高,复发未增加。
  • 已开发针对单类I HLA错配供受者对的PBM匹配网络工具。

核心结论

  • PBM-GVH错配可提示单类I HLA错配非亲缘供者移植后的死亡风险,作者认为前瞻性考虑方向性PBM匹配状态可能改善结局。
  • 这些发现强调错配HLA之间的免疫肽组差异是决定非亲缘供者移植临床耐受性的驱动因素。

研究设计与样本

  • 研究分析了2008至2018年间为急性白血病或骨髓增生异常综合征实施的2391例单类I HLA错配和14426例全HLA相合非亲缘供者造血细胞移植。
  • 采用实验确定的肽结合基序层次聚类作为HLA-A、-B或-C错配免疫肽组差异的替代指标,将1629/2391(68.1%)例HLA错配移植分类为PBM匹配或PBM错配。
  • 采用Cox比例风险模型评估PBM匹配状态相关风险,主要终点为总生存。

主要发现

  • 与全相合相比,移植物抗宿主方向双向或单向PBM错配(PBM-GVH错配,占60.7%)与显著更低的总生存相关(HR 1.48;P<.0001)。
  • 与全相合相比,宿主抗移植物方向单向PBM错配或PBM匹配(PBM-GVH匹配,占39.3%)与总生存无显著关联(HR 1.13;P=.1017)。
  • 直接比较中,PBM-GVH错配者的总生存显著低于PBM-GVH匹配者(HR 1.32;P=.0036)。
  • 移植相关死亡以及急性和慢性移植物抗宿主病的风险从全HLA相合到单PBM-GVH匹配再到单PBM-GVH错配逐步升高,但复发风险未增加。
  • 已开发用于单类I HLA错配供受者对PBM匹配的网络工具。

临床怎么用

  • 原文结论指出PBM-GVH错配可提示单类I HLA错配非亲缘供者移植后的死亡风险,作者认为前瞻性考虑方向性PBM匹配状态可能改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immunopeptidome divergence between mismatched HLA-DP is a determinant of T-cell alloreactivity and clinical tolerability after fully HLA-A, -B, -C, -DRB1, -DQB1 matched unrelated donor hematopoietic cell transplantation (UD-HCT). Here, we tested this concept in HLA-A, -B, and -C disparities after single class I HLA-mismatched UD-HCT. PATIENTS AND METHODS: We studied 2,391 single class I HLA-mismatched and 14,426 fully HLA-matched UD-HCT performed between 2008 and 2018 for acute leukemia or myelodysplastic syndromes. Hierarchical clustering of experimentally determined peptide-binding motifs (PBM) was used as a proxy for immunopeptidome divergence of HLA-A, -B, or -C disparities, allowing us to classify 1,629/2,391 (68.1%) of the HLA-mismatched UD-HCT as PBM-matched or PBM-mismatched. Risks associated with PBM-matching status were assessed by Cox proportional hazards models, with overall survival (OS) as the primary end point. RESULTS: Relative to full matches, bidirectional or unidirectional PBM mismatches in graft-versus-host (GVH) direction (PBM-GVH mismatches, 60.7%) were associated with significantly lower OS (hazard ratio [HR], 1.48; P < .0001), while unidirectional PBM mismatches in host-versus-graft direction or PBM matches (PBM-GVH matches, 39.3%) were not (HR, 1.13; P = .1017). PBM-GVH mismatches also had significantly lower OS than PBM-GVH matches in direct comparison (HR, 1.32; P = .0036). The hazards for transplant-related mortality and acute and chronic graft-versus-host disease but not relapse increased stepwise from full HLA matches to single PBM-GVH matches, and single PBM-GVH mismatches. A webtool for PBM-matching of single class I HLA-mismatched donor-recipient pairs was developed. CONCLUSION: PBM-GVH mismatches inform mortality risks after single class I HLA-mismatched UD-HCT, suggesting that prospective consideration of directional PBM-matching status might improve outcome. These findings highlight immunopeptidome divergence between mismatched HLA as a driver of clinical tolerability in UD-HCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Crivello P, Arrieta-Bolaños E, He M, et al. Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation. J Clin Oncol. 2023. PMID: 36669145. doi:10.1200/JCO.22.01229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。